

1 **Universal digital high resolution melt analysis for the diagnosis of bacteremia**

2  
3 April Aralar,<sup>a</sup> Tyler Goshia,<sup>a</sup> Nanda Ramchandar,<sup>b,c</sup> Shelley M. Lawrence,<sup>d</sup> Aparajita Karmakar,<sup>e</sup>  
4 Ankit Sharma,<sup>e</sup> Mridu Sinha,<sup>e</sup> David T. Pride,<sup>f</sup> Peiting Kuo,<sup>f</sup> Khriisa Lecrone,<sup>f</sup> Megan Chiu,<sup>f</sup>  
5 Karen Mestan,<sup>g</sup> Eniko Sajti,<sup>g</sup> Michelle Vanderpool,<sup>h</sup> Sarah Lazar,<sup>g</sup> Melanie Crabtree,<sup>g</sup> Yordanos  
6 Tesfai,<sup>g</sup> Stephanie I.Fraley<sup>a\*</sup>#

7  
8 <sup>a</sup>Department of Bioengineering, University of California, San Diego, La Jolla, CA, USA

9 <sup>b</sup>Department of Pediatrics, Naval Medical Center San Diego, San Diego, CA, USA

10 <sup>c</sup>Department of Pediatrics, Division of Infectious Diseases, University of California, San Diego,  
11 La Jolla, CA, USA

12 <sup>d</sup>Department of Pediatrics, Division of Neonatology, The University of Utah, Salt Lake City, UT,  
13 USA

14 <sup>e</sup>MelioLabs, Inc, Santa Clara, CA, USA

15 <sup>f</sup>Department of Pathology, University of California, San Diego, La Jolla, CA, USA

16 <sup>g</sup>Department of Pediatrics, Division of Neonatology, University of California, San Diego, La Jolla,  
17 CA, USA

18 <sup>h</sup>Department of Pathology and Laboratory Medicine, Rady Children's Hospital – San Diego, San  
19 Diego, San Diego, CA, USA

20  
21 Running Head: Pathogen ID and quantification in blood using UdHRM

22 #Address correspondence to Stephanie I. Fraley, [sifraley@eng.ucsd.edu](mailto:sifraley@eng.ucsd.edu).

23 \*Present address: Stephanie Fraley, University of California, San Diego, 9500 Gilman Drive,  
24 MC0435, La Jolla, CA 92093, USA

25

## 26 **Universal digital high resolution melt analysis for the diagnosis of bacteremia**

27  
28 April Aralar, Tyler Goshia, Nanda Ramchandar, Shelley M. Lawrence, Aparajita Karmakar, Ankit  
29 Sharma, Mridu Sinha, David Pride, Peiting Kuo, Khriisa Lecrone, Megan Chiu, Karen Mestan,  
30 Eniko Sajti, Michelle Vanderpool, Sarah Lazar, Melanie Crabtree, Yordanos Tesfai, Stephanie I.  
31 Fraley

### 32 **ABSTRACT**

34 Fast and accurate diagnosis of bloodstream infection is necessary to inform treatment decisions  
35 for septic patients, who face hourly increases in mortality risk. Blood culture remains the gold  
36 standard test but typically requires ~15 hours to detect the presence of a pathogen. Here, we  
37 assess the potential for universal digital high-resolution melt (U-dHRM) analysis to accomplish  
38 faster broad-based bacterial detection, load quantification, and species-level identification  
39 directly from whole blood. Analytical validation studies demonstrated strong agreement between  
40 U-dHRM load measurement and quantitative blood culture, indicating that U-dHRM detection is  
41 highly specific to intact organisms. In a pilot clinical study of 21 whole blood samples from  
42 pediatric patients undergoing simultaneous blood culture testing, U-dHRM achieved 100%  
43 concordance when compared with blood culture and 90.5% concordance when compared with  
44 clinical adjudication. Moreover, U-dHRM identified the causative pathogen to the species level  
45 in all cases where the organism was represented in the melt curve database. These results  
46 were achieved with a 1 mL sample input and sample-to-answer time of 6 hrs. Overall, this pilot  
47 study suggests that U-dHRM may be a promising method to address the challenges of quickly  
48 and accurately diagnosing a bloodstream infection.

### 49 **INTRODUCTION**

51 Sepsis is among the most common causes of death in hospitalized patients. One out of every  
52 five deaths worldwide are estimated to be due to sepsis-related complications, with 41%  
53 occurring in children.<sup>1</sup> Early detection of the infectious cause is critical for sepsis survival, as  
54 every hour the infection goes undiagnosed or inaccurately treated mortality risk rises by 4%.<sup>2-4</sup>  
55 However, rapid diagnosis of bloodstream infection (BSI) has proven to be extremely  
56 challenging.<sup>5</sup> Blood culture remains the gold-standard test despite significant false positive and  
57 negative error rates and slow time-to-result, ranging from ~15 hours to 5 days.<sup>6-12</sup>  
58 Consequently, treatments remain un-targeted, contributing to antimicrobial resistance and  
59 opportunistic infections.

60  
61 Nucleic acid amplification tests (NAATs) have been heralded as the solution to this challenge.  
62 However, NAATs are associated with higher rates of bacterial DNA detection compared to  
63 bacterial growth in blood culture. They also detect bacterial DNA in the blood of healthy  
64 patients, which has constrained their impact and widespread adoption by the medical  
65 community. For example, multiplexed PCR detection of microbial DNA in blood suffers from  
66 false positives that overestimate the concentration of pathogens in clinical samples.<sup>13-15</sup> False  
67 negatives also arise from low concentrations of pathogens and subsampling errors.<sup>16-18</sup>  
68 Likewise, the off-target interaction of primers with human DNA, which vastly outnumbers  
69 bacterial DNA in blood, can contribute to both false-positive and false-negative test results.<sup>19-26</sup>

70 These limitations extend to commercialized PCR-based strategies such as Iridica, Septifast, and  
71 SeptiTest.<sup>7,12</sup>

72  
73 Sequencing technologies have recently emerged in an attempt to address some of the  
74 limitations of more targeted NAATs, but have had limited utility in actual clinical settings.<sup>27-32</sup>  
75 Their primary advantage is broad-based detection, but they detect a wide variety of background  
76 DNA of no clinical significance, making the interpretation of their results difficult.<sup>19,29,30,33</sup> Recent  
77 studies show that they can be helpful in cases of rare pathogens, but add little to no clinical  
78 value otherwise.<sup>27,28,34,35</sup> Additionally, sequencing results are not quantitative, a feature which  
79 may help in distinguishing symptomatic infections from colonization or contamination.<sup>28,32</sup> They  
80 are also limited to the send-out format of testing due to their high complexity, batch processing,  
81 large format equipment, and expertise required to run and analyze the data.<sup>36-40</sup> Therefore, they  
82 cannot be implemented in typical hospital labs. Most importantly, multiple studies have shown  
83 that sequencing take even longer than the average blood culture to report an answer.<sup>27,28</sup>

84  
85 Towards advancing the field of BSI diagnostics, we have developed an approach called  
86 universal digital high-resolution melt analysis (U-dHRM)<sup>41-43</sup>, which conducts universal bacterial  
87 amplification in digital PCR (dPCR) followed by digital high resolution melt (dHRM) analysis of  
88 DNA amplicons to identify and quantify organisms by their sequence-specific melt curve  
89 fingerprints with machine learning (ML)<sup>44,45</sup>. This approach distinguishes itself from standard  
90 NAAT HRM-based diagnostics by its potential for unbiased broad-based pathogen identification,  
91 absolute quantification of organism(s) load (even in polymicrobial samples), and capability to  
92 expand organism identification without assay redesign. To achieve breadth and specificity, U-  
93 dHRM relies on probe-free melting of long amplicons covering extensive sequence  
94 hypervariability in barcoding genomic regions and uses all the temperature points of multimodal  
95 melt curve signatures in a T<sub>m</sub>-independent manner to identify organisms.<sup>44,45</sup> Absolute  
96 quantification and single genome analysis is achieved by digital partitioning of genomes into  
97 separate reactions for individual melt analysis and quantification.<sup>46,47</sup> Previous work established  
98 proof-of-principal for these functions.<sup>44,45</sup>

99  
100 Here, we advanced U-dHRM for analytical and clinical performance testing directly from whole  
101 blood matrix. Sample preparation techniques that enrich for intact pathogens were integrated  
102 upstream of U-dHRM and universal bacterial primers were optimized to limit off-target  
103 interactions with human DNA that carries over from blood during extraction. To power reliable  
104 ML classification on clinical samples, thousands of digital training curves were generated for 11  
105 clinically relevant pathogens spiked into whole blood. The performance of this advanced U-  
106 dHRM workflow was tested on 21 patient samples, where it achieved accurate and fast  
107 organism identification and quantification directly from whole blood in 6 hr.

## 108 109 **METHODS**

### 110 ***Whole Blood Sample Preparation***

111 The Molysis Complete 5 kit (Molzylm GmbH & Co. KG, Bremen, Germany) was selected for  
112 whole blood sample preparation prior to U-dHRM analysis. Molysis is designed to deplete host  
113 DNA and enrich for microbial DNA from intact cells. The residual concentration of human DNA

114 following Molysis processing of 1mL whole blood was quantified by dPCR with  $\beta$ -actin gene  
115 primers (see PCR Master Mixes section for details) to be  $4.67 \times 10^2$ - $5.67 \times 10^3$  copies/ $\mu$ L in the  
116 sample extraction elute (Supplementary Fig. 1). This indicated that human DNA can carryover  
117 into a significant proportion of the available partitions of the dPCR chip during U-dHRM analysis  
118 and prompted the screening of universal bacterial 16S primers for off-target interactions with  
119 human DNA, given their known homology<sup>19</sup>.

120

### 121 **Primer Selection and Internal Amplification Control**

122 Universal primer sequences were identified through literature review and tested in BLAST for  
123 alignment to the human genome. Apart from V6R which was used as a control sequence,  
124 primer sequences were selected for screening if there was <85% query coverage. As an  
125 additional strategy for promoting the detection of intact microbes, primer pairs were required to  
126 produce a long amplicon (>600 bp) capable of discriminating against degraded DNA.<sup>48-50</sup>  
127 Amplicons were also required to include the important hypervariable regions (V4 and V6) for  
128 differentiation of the greatest number of bacterial species.<sup>51</sup> Supplementary Table 1 lists the  
129 primer pairs selected for screening and their characteristics.

130

131 To assess off-target interactions, human genomic DNA was extracted from healthy cord blood  
132 using the Wizard Genomic DNA Purification Kit (Promega, Madison, WI) and spiked into qPCR  
133 reactions at post-Molysis concentrations (approximately 1 ng/ $\mu$ L DNA based on  
134 spectrophotometer reading) with 16S primers. Results were confirmed in dPCR. In qPCR,  
135 several primer pairs amplified earlier than others and produced melt curves that were consistent  
136 within a primer pair (Supplementary Fig. 2A), suggesting off-target yet reliable interactions.  
137 V1F/V9R showed no off-target amplification in qPCR, indicated by the absence of both a cycle  
138 threshold (Ct) curve and a melt curve (Supplementary Fig. 2A). Similar results were found in  
139 dPCR. Supplementary Fig. 2B shows the amplified partitions from dPCR and the resultant  
140 dHRM melt curves for each primer pair. Taller and more consistent melt curves indicate  
141 stronger interactions between the primers and the human DNA. The V1F/V9R primer pair  
142 produced the smallest number of off-target curves, and they were noisy, short, and inconsistent,  
143 indicating weak and rare interactions (Supplementary Fig. 2C, green box). The number of off-  
144 target melt curves counted for each primer pair is shown in Supplementary Fig. 2C. Additional  
145 testing with no template control (PCR water) and bacterial DNA (*E. coli*) further demonstrated  
146 that V1F/V9R has low off-target and high on-target amplification (Supplemental Fig. 3).

147

148 V1F/V9R was then confirmed in qPCR to amplify bacterial gDNA extracted from different  
149 species representing common bloodborne pathogens in the pediatric population  
150 (Supplementary Table 2)<sup>52</sup>. Supplementary Fig. 4A shows the alignment of the primer pair to the  
151 16S gene of each organism, and Supplementary Fig. 4B shows singular, consistent melting  
152 curves for each of the bacterial amplicons, indicating that amplification was specific. With the  
153 addition of post-Molysis levels of human DNA (Supplementary Fig. 4C), similar melt curves  
154 were produced. Their amplitude was slightly lower, suggesting that slight dPCR amplification  
155 inhibition occurs in the presence of residual human DNA. These qPCR results verified that  
156 V1F/V9R is capable of broad-based bacterial DNA amplification and exclusion of human DNA  
157 amplification at concentrations expected following host DNA depletion by Molysis.

158  
159 Finally, the behavior of the V1F/V9R primers were evaluated in dPCR for contrived bacteremic  
160 blood samples pre-processed by Molysis. For these experiments, we also included our  
161 previously developed internal amplification control (IAC) that improves quantification in dPCR<sup>53</sup>.  
162 The IAC generates an amplicon that melts at a lower temperature than bacterial amplicons in  
163 dHRM. We verified that the IAC assay components do not interact with V1F/V9R by generating  
164 blood matrix spike (MS) samples with *E. coli* or no template control (NTC) samples with sterile  
165 PBS, processing them with Molysis, and analyzing them by U-dHRM. Supplementary Fig. 5A  
166 shows that for the *E. coli* spiked sample, both the IAC and *E. coli* melt curves or the IAC melt  
167 curves alone or no melt curves are produced per partition at expected levels. Supplementary  
168 Fig. 5B shows that the NTC sample only generated melt curves for the IAC or were negative for  
169 amplification. IAC negative reactions are excluded during concentration calculations to improve  
170 quantification.<sup>53</sup>

### 171 172 **PCR Master Mixes**

173 All PCRs were performed using a 15- $\mu$ L total reaction volume. All PCR reactions with the  
174 exception of those conducted for identity verification by sequencing and human DNA  
175 quantification experiments consisted of 1 $\times$  Phusion GC PCR buffer (Thermo Scientific,  
176 Waltham, MA), 2 $\times$  ROX dye (Bio-Rad, Hercules, CA), 0.02  $\mu$ M IAC primers, 0.1  $\mu$ M IAC  
177 template, 0.1  $\mu$ M each bacterial primer (IDT), 2.5 $\times$  EvaGreen (Biotium, Fremont, CA), 0.2 mM  
178 deoxynucleoside triphosphate (dNTP) (Invitrogen, Carlsbad, CA), 0.02 U/ $\mu$ L Phusion  
179 polymerase (New England Biolabs, Ipswich, MA), 3  $\mu$ L of genomic DNA dilution, and ultrapure  
180 water (Quality Biological, Gaithersburg, MD). Identification verification and human DNA  
181 quantification experiments were performed in qPCR without the IAC template and bacterial  
182 primers in the master mix.

183  
184 The following  $\beta$ -actin primer sequences were used<sup>54</sup>: Forward 5'-  
185 CGGCCTTGGAGTGTGTATTAAGTA-3', Reverse 5'-TGCAAAGAACACGGCTAAGTGT-3'.

186  
187 The internal control template and primer were used at the concentrations determined previously  
188 to promote amplification in a maximum number of wells without outcompeting the amplification  
189 of low-level bacterial targets.<sup>53</sup> The IAC template sequence is as follows<sup>53</sup>: 5'-  
190 CCATAGACGTAGCAACGATCGTGAGGTAGTAGATTGTATAGTTGATGCAAGGACTA  
191 TCCACTCAC-3'. The IAC was linearly amplified using only a forward primer 5'-  
192 CGATCGTTGCTACGTCTATGG-3'.

### 193 194 **PCR and HRM Cycling Conditions**

195 The qPCR experiments were performed on a Bio-Rad CFX 96 (Bio-Rad, Hercules, CA). U-  
196 dHRM thermocycling was performed on a ProFlex 2 x Flat Block Thermal Cycler (Applied  
197 Biosystems, Waltham, MA). For  $\beta$ -actin amplification, thermocycling for both dPCR and qPCR  
198 proceeded as follows: hold at 98°C for 30 s, followed by 70 cycles of 98°C for 10 s, 65.2°C for  
199 30 s, and 72°C for 45 s. For all other reactions, thermocycling for both dPCR and qPCR  
200 proceeded as follows: hold at 98°C for 30 s, followed by 70 cycles of 98°C for 10 s, 62°C for 30  
201 s, and 72°C for 45 s. qPCR amplification was followed by a melt cycle of 95°C for 15 s, 45°C for

202 60 s, and 96°C for 5 s). dPCR amplification was followed by a melt cycle on a Melio MeltRead™  
203 Platform dHRM heating device and simultaneously imaged on a custom Olympus microscope  
204 setup as previously described.<sup>46,55</sup>

205

### 206 **Generation of Spiked and Control Blood Samples**

207 Eleven bacterial species were obtained from either the American Type Culture Collection  
208 (ATCC), from the Pride Lab at the University of California at San Diego (UCSD), or from the  
209 Microbiology Lab at Rady Children's Hospital, San Diego (RCHSD). The bacteria were cultured  
210 in liquid media according to ATCC guidelines. To verify organism identities, genomic DNA from  
211 each species was extracted using the Wizard Genomic DNA purification kit (Promega  
212 Corporation, Madison, WI). The DNA concentration was measured by biospectrophotometer  
213 and diluted in one 10-fold serial dilution before undergoing qPCR amplification with 16S primers.  
214 DNA products were then sent for Sanger sequencing.

215

### 216 *Melt Curve Database*

217 To generate the melt curve database for these organisms, each bacterial species was cultured  
218 in liquid culture in the ATCC recommended broth overnight, and 1 mL of freshly prepared  
219 bacterial suspension was centrifuged and resuspended in sterile PBS. The turbidity was  
220 adjusted to  $OD_{600} = 1$ , measured on an biospectrophotometer. Each species of bacteria was  
221 spiked into 2 mL of healthy human cord blood at a ratio of 1:10 bacterial suspension to blood.  
222 The sample was then split, with 1 mL cultured on agar plates to verify bacterial growth while the  
223 other mL went through the Molysis Complete 5 Microbial DNA isolation protocol (Molzym,  
224 Bremen, Germany). DNA products were amplified by qPCR and identity verified by Sanger  
225 sequencing. Following identity verification, DNA samples were diluted in one ten-fold dilution  
226 and analyzed by U-dHRM as described above. This spiking and extraction process was  
227 performed twice for each organism to encompass 2 biological replicates, and technical  
228 replicates were created from each extraction. Each organism had a total of 8 chips analyzed to  
229 create the bacterial melt curve database. The melt curves from each organism were combined  
230 and clustered according to the ML algorithm described below and in the supplemental materials.  
231 Representative melt curves were generated by the ML algorithm, aligned by their highest peaks,  
232 and averaged (see Supplementary Methods).

233

### 234 *Analytical Validation Studies*

235 Mock samples for analytical validation studies were generated in a similar manner. Briefly, *E.*  
236 *coli* was cultured in LB broth overnight, and 1 mL of freshly prepared bacterial suspension was  
237 centrifuged and resuspended in sterile PBS. The turbidity was adjusted to  $OD_{600} = 0.5$ ,  
238 measured on an Eppendorf Biospectrophotometer. Six 10-fold serial dilutions were conducted to  
239 achieve concentrations down to 0.1 CFU/mL. Bacteria from each concentration were spiked into  
240 2 mL of healthy human cord blood to achieve the final concentrations of 10k, 1k, 100, 10, 1 and  
241 0.1 bacterial cells/mL of blood. Concurrently, an NTC sample was prepared by adding sterile  
242 PBS to the blood at the same volume as the bacterial spike. One mL of each sample was split  
243 off and underwent Molysis Complete 5 Microbial DNA isolation and quantification by U-dHRM.  
244 The other mL of blood underwent quantitative blood culture (QBC) by plating 100  $\mu$ L of blood on  
245 10 agar plates to verify bacterial growth and quantity CFU.

246  
247 Elution blank samples were also prepared to assess the level of background in the reagents and  
248 disposables. These were generated following Molzym's standard negative control test  
249 procedure, which consists of processing 1mL of SU buffer (included in the Molysis Complete 5  
250 Kit) through the standard Molysis microbial DNA isolation protocol. Three elution blanks were  
251 processed and each was analyzed by U-dHRM across 6 chips following the same procedure as  
252 was used for the spiked matrix samples.

### 253 254 ***Clinical Sample Testing Procedure***

255 For all scavenged whole blood samples, 1 mL of blood was processed by the Molysis Complete  
256 5 kit (Molzym, Bremen, Germany). Immediately afterwards, the DNA elute was processed  
257 concurrently by qPCR detection and U-dHRM quantification using the PCR master mix formulas  
258 for bacterial amplification and the PCR protocols described above. Three reactions were run for  
259 qPCR testing and three reactions were performed in U-dHRM for each sample. For each  
260 method, 9  $\mu$ L total was sampled out of the 100  $\mu$ L elute.

### 261 262 ***Clinical Samples Scavenging Protocol and Inclusion/Exclusion Criteria***

263 The study protocol was reviewed and approved by the Institutional Review Board (IRB) and  
264 Ethics Committee (No. 191392) of the University of California, San Diego (UCSD) and Rady  
265 Children's Hospital in San Diego (RCHSD). A materials transfer agreement (MTA) between  
266 RCH and UCSD was executed to enable sample transfer. The age ranges of samples used for  
267 this study are shown in Supplementary Table 3. In total, 21 samples were scavenged that met  
268 inclusion/exclusion criteria as defined below. Among both positive and negative scavenged CBC  
269 samples, 42.9% of the samples were female and 57.1% were male. Racially, 19% of the  
270 samples were Asian, 9.5% were black or African American, 28.6% were Hispanic/Latino/Latinx,  
271 and 42.9% were White.

### 272 273 ***Positives***

274 Remnant CBC samples were scavenged from the RCHSD hematology lab. CBCs were tagged  
275 for scavenging if a blood culture result from the same patient was flagged positive in RCHSD's  
276 clinical microbiology lab. Once a CBC was tagged for collection, an honest broker de-identified  
277 the sample and logged sample characteristics. The sample was then transferred to UCSD and  
278 processed by U-dHRM the same day. Scavenged CBCs were excluded if they did not meet the  
279 following criteria:

- 280 (1) The CBC and positive blood culture sample were drawn at the same time (within 1  
281 minute).
- 282 (2) No antibiotics were administered within the same hospital visit prior to collection.
- 283 (3) At least one milliliter was scavenged.

284  
285 Seven CBC samples met these criteria during the collection timeframe. It is important to note  
286 that these blood samples were first held at room temperature prior to CBC processing and were  
287 then transferred to refrigerated storage at 4°C in the clinical microbiology lab, where there was a  
288 minimum 24-hour hold time until the sample was released to be scavenged. Most pathogenic  
289 bacteria do not grow under such conditions<sup>56,57</sup>, so it is unlikely that this hold time would

290 substantially increase the bacterial load that U-dHRM quantifies. However, it is possible that  
291 some bacterial cell death occurs during this time.

292  
293 To assess this possibility, we conducted mock sample aging studies. Briefly, *E. coli* was  
294 cultured in LB broth overnight, and 1 mL of freshly prepared bacterial suspension was  
295 centrifuged and resuspended in sterile PBS. The turbidity was adjusted to  $OD_{600} = 0.5$ ,  
296 measured on a biospectrophotometer. Ten-fold serial dilutions were conducted and bacteria  
297 from two concentrations were spiked into 2 mL of healthy human cord blood to achieve the final  
298 concentrations of 10,000 and 1,000 bacterial cells/mL of blood. The 2mL sample was then split:  
299 1mL was immediately processed and 1mL was stored at 4°C for 24 hours before being processed by the  
300 Molysis DNA extraction method and subsequent U-dHRM analysis. The measured concentrations of  
301 bacteria were compared before and after refrigeration. This experiment was conducted 3 times. A  
302 slight but insignificant drop in was detected after refrigeration at both spike concentrations, as  
303 shown in Supplemental Fig. 6. While this is not an exhaustive sample aging study, it suggests  
304 that the number of organisms detected in the CBC samples may not be strongly impacted by  
305 refrigerated storage time. It is important to note that our molecular detection approach only  
306 requires organisms to be intact such that their gDNA is protected from degradation during  
307 Molysis sample preparation. Viability or culturability is not a requirement for detection by U-  
308 dHRM.

309

#### 310 *Negatives*

311 Within the same IRB protocol described above, remnant CBCs matched to blood culture  
312 negative samples were scavenged from RCHSD. CBCs were tagged for scavenging if a blood  
313 culture result from the same patient resulted as negative in RCHSD's clinical microbiology lab.  
314 Once a CBC was tagged for collection, an honest broker de-identified the sample and logged  
315 sample characteristics. The sample was then transferred to UCSD and processed by U-dHRM  
316 the same day. During the collection timeframe, 14 negative samples were scavenged. The  
317 majority of these were found to have had antibiotic exposure at the time of blood draw.  
318 Therefore, we amended our exclusion criteria for negatives to ensure sufficient sample size.  
319 Scavenged negative CBCs were excluded if they did not meet the following criteria:

- 320 (1) The CBC and blood culture negative sample were drawn at the same time (within 1  
321 minute)
- 322 (2) At least one milliliter was scavenged

323

#### 324 ***U-dHRM Data Curation, Preprocessing, and Melt Curve Classification***

325 A detailed description of the melt curve analysis methods, including the Python packages used,  
326 can be found in the Supplementary Methods. Briefly, we employed an optimized image  
327 processing, melt curve preprocessing, and machine learning (ML) pipeline for extracting,  
328 analyzing, and classifying curves. Fluorescence data extraction from dPCR chips imaged during  
329 the dHRM heating process was performed using the protocol detailed in <sup>53</sup>, and with appropriate  
330 temperature-to-time mapping, each resulting raw melt curve was converted to a time series  
331 (TS). These fluorescence TS were converted to derivative TS and filtered using several peak-  
332 based criteria. Finally, TS smoothing, cropping, and normalizations were performed to  
333 preprocess the data into a format appropriate for the downstream ML algorithms.



334  
335 A two-step classification process was developed for derivative TS classification. Since the melt  
336 curves have significant variations and noise within and between chips, K-means clustering was  
337 used as a first step to extract the key clusters of variations along with respective cluster centers,  
338 which are more robust compressed signals. In the second step, a k-Nearest Neighbour (kNN)  
339 classifier was used to classify a test curve by comparing its distance from the cluster centers  
340 from the first step. Both the Dynamic Time Warping (DTW) distance, which can take y-axis  
341 scaling or x-axis shifting variations into account, and the Euclidean distance are measured, and  
342 compared for agreement. If the closest organism call matches by both DTW and Euclidean  
343 distance, then the test cluster is confidently called as that respective organism. If the DTW and  
344 Euclidean calls do not match, the cluster is considered “low confidence”. Low confidence called  
345 clusters can stem from noisy signals, or from novel curves that may not be represented in the  
346 database yet.

347  
348 Classification accuracy was assessed for the database of organism melt curves by dividing the  
349 database curves into training and test sets and conducting cross validation experiments. For  
350 patient samples, the extracted TS are first clustered using DTW-based K-means, and the  
351 obtained cluster centers, or representatives, are classified using the kNN-based classifier that  
352 was built using the database curves.

### 353 354 **Statistical Analysis**

355 All statistical analyses were performed in Graphpad Prism 5 (Dotmatics, Boston, MA). A one-  
356 way analysis of variance (ANOVA) was conducted on the analyzed testing groups (extraction  
357 blanks, culture negative matched CBCs, and culture positive matched CBCs) with a Bonferroni  
358 posttest to compare all pairs of columns.

## 359 360 361 **RESULTS**

362  
363 **Digital Melt Curve Database Generation and Classification in Spiked Whole Blood Matrix**  
364 Whole blood matrix spike (MS) samples were generated for 11 organisms (Supplementary  
365 Table 2), representing some of the most common causes of BSI among pediatric patients<sup>52</sup>, and  
366 analyzed by U-dHRM with primers targeting the V1-V9 regions of the bacterial 16S rRNA gene.  
367 Fig. 1A shows representative melt curves for each organism, highlighting the clear visual  
368 differences between the V1-V9 melt curve fingerprints. Raw curves can be seen in  
369 Supplementary Fig. 7. Coagulase-negative staphylococci (CoNS) species (*S. hominis* and *S.*  
370 *epidermidis*) were combined since their treatment does not differ and they are often considered  
371 contaminants. A ML algorithm, which relies on agreement between two classification strategies  
372 (see Methods section), demonstrated an average of 97% classification accuracy on this dataset,  
373 which included >146,000 training curves (Supplementary Table 4). The number of curves  
374 (support) that were used in this analysis for each organism is also detailed in Supplementary  
375 Table 4. A confusion matrix resulting from leave one out cross validation (LOOCV) experiments  
376 is shown in Fig. 1B. Consistent with the classification accuracy score of 97%, the confusion  
377 matrix shows that the vast majority of digital melt curves are classified as the correct organism.

378 Misclassifications occurred rarely, mostly in the *Staphylococcus* genus. These results  
379 demonstrate the ability of V1-V9 U-dHRM combined with ML to reliably and automatically  
380 differentiate organisms in spiked blood samples.

381

### 382 **Analytical Validation**

383 As a preliminary assessment of quantitative power of U-dHRM, six concentrations of *E. coli*  
384 were spiked into a healthy human blood matrix and compared to a no template control (PBS)  
385 spiked blood samples. These samples were split in half and underwent paired testing by U-  
386 dHRM analysis and quantitative blood culture (QBC) (Fig. 2A). U-dHRM quantification showed  
387 excellent agreement with QBC in the concentration range of 10,000-10 CFU/mL, with a Pearson  
388 r value of 0.9988 and a p-value of 0.0012 (Fig. 2B). However, at concentrations below 10  
389 CFU/mL, detection variability increased as a result of the extraction elute volume sampled by U-  
390 dHRM. From 1mL of blood, extraction elutes 100ul and U-dHRM sampled 9ul of this elute  
391 across three chips (3ul each). This results in 1 curve detected per 3 chips equating to 11.1  
392 CFU/mL, and limits quantification below this level. For this reason, when bacteria are spiked at  
393 dilutions lower than 10 CFU/mL, U-dHRM quantifies bacteria at 0 CFU/mL (0 curves) or 10  
394 CFU/mL (1 curve). However, for practical reasons, we continued with this format for this pilot  
395 study. Extraction blank (EB) samples were tested according to the manufacturer recommended  
396 negative control method, which showed a very low level of background originating from the  
397 reagents and/or disposables used in the process (Fig. 2B). ML classification of these curves  
398 against our database did not identify any matches to the database organisms.

399

### 400 **Pilot Clinical Testing**

401 Next, we conducted U-dHRM analysis on 21 whole blood samples from patients ranging in age  
402 from infants to toddlers (Supplementary Table 3). These were remnants of complete blood  
403 count (CBCs) that were drawn from pediatric patients undergoing blood culture for suspicion of  
404 BSI. Only CBCs drawn at the same time from the same location as a blood culture draw were  
405 included (see Methods section). Of these 21 samples, 14 were matched to negative cultures  
406 and 7 were matched to positive cultures. Clinician adjudication of blood culture results was  
407 performed by a practicing physician in the Department of Pediatrics, Division of Infectious  
408 Diseases at Rady Children's Hospital. The clinician reviewed the charts for each patient and  
409 each specific sample to determine if the blood culture results indicated a probable infection  
410 when compared to patient inflammatory markers, final diagnosis, additional diagnostic tests,  
411 success of prescribed treatment, and any other relevant clinical information. A summary of  
412 blood culture results, clinical diagnostic details for each sample, and clinician adjudicated  
413 diagnosis for blood culture positive samples is presented in Table 1.

414

415 The machine learning algorithm, which was trained to classify database curves from spiked  
416 blood samples (Fig. 1), was used to automatically classify melt curves detected in the patient  
417 samples. Melt curves were determined to be either a high or low confidence match to the  
418 database organisms, or unmatched. Algorithms for high confidence, low confidence, and  
419 unmatched calling are detailed in the Methods and Supplemental Methods sections.

420

### 421 **Results for CBC Negative Samples**

422 All of the 14 CBC samples matched to negative blood cultures were reported to be negative for  
423 any organism curves by the ML algorithm.

424

### 425 **Results for CBC Positive Samples**

426 In positive CBC samples 1-5, ML curve classification identified high confidence matches to the  
427 same organisms identified by blood culture (Table 1). Representative melt curves detected by  
428 ML classification are shown in Fig. 3 A-I. In a few cases, additional organisms were detected by  
429 U-dHRM. In sample 3 where *S. enterica* was the primary pathogen detected by both BCID and  
430 U-dHRM (Fig. 3C), *S. maltophilia* was also detected at lower levels by U-dHRM (Fig. 3D). In  
431 sample 5, where *S. enterica* was detected by BCID and U-dHRM (Fig. 3F), *S. aureus* was also  
432 detected by U-dHRM (Fig. 3G).

433

434 CBC samples 6 and 7 had discordant BCID and U-dHRM organism identifications. In sample 6,  
435 blood culture found gram positive rods (GPR) and post-culture ePlexID identified *Bacteroides*.  
436 Clinical adjudication determined this to be a false positive (Table 1). U-dHRM detected CoNS  
437 with high confidence (Fig. 3H).

438

439 In sample 7, blood culture found gram negative rods (GMR) and post-culture ePlexID identified  
440 *Enterobacter non cloacae*. However subsequent blood draws on this patient resulted in later  
441 detection of *Klebsiella* by BCID and clinician adjudication confirmed *Klebsiella* BSI (Table 1). U-  
442 dHRM did not identify high confidence matches in this sample, but did identify low confidence  
443 matches to *K. pneumoniae* (Fig. 3I). Low confidence matches for all samples are shown with  
444 their closest database matches in Supplementary Figures 8-11.

445

446 Fig. 3J shows the bacterial load quantified by U-dHRM in each CBC sample for high confidence  
447 matches. The time to result (TTR) for U-dHRM, 6hr, was substantially faster than BCID in all  
448 cases (Table 1). U-dHRM ranged from 7.5hr to 2d 18hr faster than BCID TTR for positives.  
449 Negatives are confirmed by BCID at 5d.

450

451 In summary, the overall concordance for the detection of bacteremia in whole blood samples  
452 was 21/21 (100%) from the perspective of blood culture as truth and 19/21 (90.5%) from the  
453 perspective of clinically adjudicated findings as truth. In the 5 samples determined to be true  
454 bacteremia by clinician adjudication, U-dHRM accurately identified the organism in 5/5, with 4  
455 high confidence matches and 1 low confidence match.

456

### 457 **DISCUSSION**

458 U-dHRM with ML achieved accurate organism identification in spiked whole blood samples and  
459 in clinical whole blood samples, suggesting that this approach can overcome a common pitfall of  
460 standard HRM where interference from biological substances in whole blood that co-extract with  
461 DNA cause large Tm shifts.<sup>58</sup> U-dHRM overcomes this by generating thousands of example  
462 curves for each organism, which are identified independently of Tm by curve shape matching  
463 using ML. Interfering substances that carryover from blood can also impact the sensitivity and  
464 quantitative power of standard PCR-based assays by reducing amplification efficiency. U-dHRM  
465 achieved excellent quantitative agreement with QBC in the range of 10,000-10 CFU/mL in

466 spiked blood by relying on endpoint detection, which overcomes efficiency bias and enables  
467 absolute quantification. Below 10 CFU/mL, U-dHRM was unable to accurately quantify because  
468 only ~10% of each 1mL sample volume was tested. This limitation can be overcome by  
469 analyzing more of the extracted sample volume, concentrating the elute, running more chips per  
470 sample, increasing the number of digital partitions, or increasing the volume of digital partitions.  
471 Nonetheless, some differences between blood culture and molecular detection approaches may  
472 persist due to the presence of viable but non-culturable cells.<sup>59</sup>

473  
474 In pilot clinical sample testing, U-dHRM demonstrated 14/14 (100%) agreement with culture  
475 negative samples. Given that universal bacterial primers form the basis of the assay, this result  
476 suggests that the testing process used was successful in limiting the detection of background  
477 and degraded DNA of no clinical significance. The sample preparation method used is  
478 specifically designed to bias detection towards DNA from intact/living bacteria cells by  
479 degrading cell-free DNA before microbe lysis. Also, the length of the V1-V9 amplicon, ~1400 bp,  
480 biases towards non-degraded DNA.

481  
482 U-dHRM also demonstrated 7/7 (100%) agreement with blood culture positivity, although two of  
483 these (samples 1 and 6) were determined by the adjudicating clinician to be false positive blood  
484 cultures. For sample 1, both BCID and U-dHRM detected CoNS. However, the final diagnosis  
485 was a urinary tract infection (UTI) caused by *E. coli*. The patient was not treated for an *S.*  
486 *epidermidis* BSI, but was treated for the UTI and improved, leading the adjudicating clinician to  
487 believe that the *S. epidermidis* was a contaminant. Since *S. epidermidis*/CoNS was detected by  
488 both methods, this was likely a true live cell contaminant. For sample 6, BCID detected  
489 *Bacteroides* while U-dHRM detected CoNS and two other curves that did not match any  
490 organisms in our database. The final diagnosis was polymicrobial skin and soft tissue infection  
491 (SSTI). In older children and adults, BCID of CoNS is usually considered to be a false positive  
492 caused by contamination, but in neonates it can indicate true BSI<sup>60</sup>. In the future, the absolute  
493 quantitative power of U-dHRM may be able to help to further refine these heuristics by defining  
494 clinically relevant load ranges that differentiate true bacteremia in need of treatment from  
495 common contamination levels for organisms that can be both pathogen and commensal.

496  
497 The U-dHRM sample to answer time was 6hr for all samples, while BCID TTR ranged from  
498 ~13.5hr to 3d for positive samples and up to 5d for negative samples. Interestingly, the positive  
499 samples with the longest TTR by blood culture (samples 2 and 3, TTR ~2d and 3d respectively)  
500 were determined to have some of the highest bacterial loads by U-dHRM. Both U-dHRM and  
501 BCID identified *S. enterica*, which is known to grow slowly in blood culture because it is an  
502 intracellular pathogen that prefers to grow in macrophages.<sup>61</sup> Blood culture and bone marrow  
503 culture are limited in their ability to recover this pathogen,<sup>62</sup> even in patients harboring loads of  
504  $1.01 \times 10^3$  to  $4.35 \times 10^4$  copies/mL.<sup>63</sup> Clinical adjudication revealed that samples 2 and 3 originated  
505 from the same patient but were taken on subsequent days. U-dHRM quantified the first blood  
506 draw from this patient (sample 2) as having three times the concentration of *S. enterica* as the  
507 second draw on the following day (sample 3). However, U-dHRM also detected *S. maltophilia* in  
508 the second draw (sample 3) at a lower concentration than *S. enterica*, which may indicate a  
509 secondary infection in this patient since *S. maltophilia* is an opportunistic pathogen. The patient

510 did not have antibiotic exposure at the time of either blood draw, so the decrease in *S. enterica*  
511 may have resulted from the patient naturally beginning to clear the infection. This highlights the  
512 possibility of using U-dHRM to track infections over time and in response to treatment.

513  
514 *S. maltophilia* was also detected by U-dHRM and BCID in sample 4. *S. maltophilia* is an  
515 emerging pathogen of concern for nosocomial infections. It is being isolated more frequently  
516 and can be found ubiquitously in hospital environments.<sup>64,65</sup> The time saved by U-dHRM  
517 detection of this organism (~7hr) could have resulted in faster treatment with appropriate  
518 antimicrobial therapies, since this organism is inherently multidrug-resistant.<sup>66</sup>

519  
520 In one case, sample 5, U-dHRM identified the causative pathogen while post-culture ePlex PCR  
521 failed. This sample took over a day to grow out in culture and be identified, meaning that U-  
522 dHRM would have provided a faster detection and identification time.

523  
524 In sample 7, U-dHRM returned low confidence calls, with one of them partially matched to the  
525 causative pathogen, *Klebsiella*. Blood culture did not identify the causative pathogen in the  
526 matched sample. However, subsequent blood cultures did identify *Klebsiella*. Unfortunately,  
527 matched U-dHRM samples for these subsequent cultures were not available. Low confidence  
528 calls result from disagreement between the two ML classification methods used, which can arise  
529 due to the organism not being in the database or due to melt curve noise, which can prevent  
530 confident classification and identification. Expansion of the digital melt curve database with  
531 more organisms and more training curves for each organism is expected to improve curve  
532 calling confidence.

533

534

## 535 **CONCLUSIONS**

536 Overall, the U-dHRM approach demonstrated 100% concordance with blood culture (positive/  
537 negative) and 90.5% concordance with clinician adjudicated blood culture results (positive  
538 BSI/negative BSI). In all samples representing true bacteremia, U-dHRM correctly identified the  
539 causative pathogen, achieving 100% concordance with the genus and species identified by  
540 culture. U-dHRM has a much faster time to result than traditional blood culture methods, and  
541 automation of the U-dHRM process is expected to further reduce the sample-to-answer time.  
542 However, this pilot study of 21 patient samples needs to be further validated by testing a larger  
543 cohort across multiple medical centers. Additional organisms will also need to be added to the  
544 database to encompass all of the most clinically relevant organisms for sepsis. Further  
545 optimization of our ML algorithm and additional training data is expected to improve the ability of  
546 U-dHRM to call organisms with high confidence as well as to discern when samples contain  
547 organisms that are not yet in the database.

548

## 549 **ETHICS**

550 The clinical study protocol was reviewed and approved by the Institutional Review Board (IRB)  
551 and Ethics Committee (No. 191392) of the University of California, San Diego (UCSD) and Rady  
552 Children's Hospital (RCHSD). Consent was not required for the scavenging of remnant CBC  
553 samples.

554

## 555 **DATA AVAILABILITY**

556 The data that support the findings of this study, in accordance with IRB designated restrictions,  
557 are available from the corresponding author upon request.

558

## 559 **ACKNOWLEDGEMENTS**

560 This work was supported by the National Institute of Allergy and Infectious Diseases of the  
561 National Institutes of Health (award number R01AI134982), a Burroughs Wellcome Fund Career  
562 Award at the Scientific Interface (award number 1012027 to S.I.F.), and UCSD CTRI, FISP, and  
563 AIM pilot grants. We acknowledge and thank MelioLabs for the use of their MeltRead Platform  
564 and for their assistance in data analysis with their ML pipeline.

565

566 S.I.F. and A.A. designed the study. A.A. conducted experiments and analyzed data with  
567 assistance from T.G. N.R. provided clinical adjudication and general guidance in interpreting  
568 clinical results. S.M.L., K.M., and E.S. provided cord blood for analytical validation and  
569 database development and additional clinician guidance. A.K., A.S, and M.S. developed the  
570 algorithm used for machine learning and used it to perform quantification and classification, and  
571 assisted in interpretation of the machine learning results. D.P., P.K., K.L, and M.C. provided  
572 clinical isolates and performed blood culture testing on samples acquired from the blood bank.  
573 M.V., S.L, M.C, and Y.T. collected clinical samples and provided the associated clinical data  
574 from Rady Children's Hospital.

575

## 576 **DISCLAIMER**

577 The views expressed in this article are those of the author(s) and do not necessarily reflect the  
578 official policy or position of the Department of the Navy, Department of Defense, or the US  
579 Government.

580

## 581 **DISCLOSURE**

582 S.I.F. is a scientific cofounder, director, and advisor of MelioLabs, Inc., and has an equity  
583 interest in the company. S.M.L. is an advisor of Melio and has equity interest. M.S. is co-founder  
584 and CEO of Melio and has equity interest. A.K. and A.S. are employees of Melio. NIAID award  
585 number R01AI134982 has been identified for conflict of interest management based on the  
586 overall scope of the project and its potential benefit to MelioLabs, Inc.; however, the research  
587 findings included in this particular publication may not necessarily relate to the interests of  
588 MelioLabs, Inc. The terms of this arrangement have been reviewed and approved by the  
589 University of California, San Diego, in accordance with its conflict of interest policies.

590

591

## 592 **REFERENCES**

- 593 1. WHO. Global report on the epidemiology and burden of sepsis: current evidence,  
594 identifying gaps and future directions. Preprint at (2020).
- 595 2. Seymour, C. W. *et al.* Time to Treatment and Mortality during Mandated Emergency Care

- 596 for Sepsis. *N. Engl. J. Med.* **376**, 2235–2244 (2017).
- 597 3. Biondi, E. A. *et al.* Blood culture time to positivity in febrile infants with bacteremia. *JAMA*  
598 *Pediatr.* **168**, 844–849 (2014).
- 599 4. Mukhopadhyay, S. *et al.* Time to positivity of blood cultures in neonatal late-onset  
600 bacteraemia. *Arch. Dis. Child. Fetal Neonatal Ed.* **107**, 583–588 (2022).
- 601 5. Eubank, T. A., Long, S. W. & Perez, K. K. Role of Rapid Diagnostics in Diagnosis and  
602 Management of Patients With Sepsis. *The Journal of Infectious Diseases* vol. 222 S103–  
603 S109 Preprint at <https://doi.org/10.1093/infdis/jiaa263> (2020).
- 604 6. Schelonka, R. L. *et al.* Volume of blood required to detect common neonatal pathogens. *J.*  
605 *Pediatr.* **129**, 275–278 (1996).
- 606 7. Sinha, M. *et al.* Emerging Technologies for Molecular Diagnosis of Sepsis. *Clin. Microbiol.*  
607 *Rev.* **31**, (2018).
- 608 8. Stranieri, I. *et al.* Assessment and comparison of bacterial load levels determined by  
609 quantitative amplifications in blood culture-positive and negative neonatal sepsis. *Rev. Inst.*  
610 *Med. Trop. Sao Paulo* **60**, e61 (2018).
- 611 9. Lancaster, D. P., Friedman, D. F., Chiotos, K. & Sullivan, K. V. Blood Volume Required for  
612 Detection of Low Levels and Ultralow Levels of Organisms Responsible for Neonatal  
613 Bacteremia by Use of Bactec Peds Plus/F, Plus Aerobic/F Medium, and the BD Bactec FX  
614 System: an *In Vitro* Study. *Journal of Clinical Microbiology* vol. 53 3609–3613 Preprint at  
615 <https://doi.org/10.1128/jcm.01706-15> (2015).
- 616 10. Hall, K. K. & Lyman, J. A. Updated review of blood culture contamination. *Clin. Microbiol.*  
617 *Rev.* **19**, 788–802 (2006).
- 618 11. Zhang, Y., Hu, A., Andini, N. & Yang, S. A ‘culture’ shift: Application of molecular  
619 techniques for diagnosing polymicrobial infections. *Biotechnology Advances* vol. 37 476–  
620 490 Preprint at <https://doi.org/10.1016/j.biotechadv.2019.02.013> (2019).
- 621 12. Venkatesh, M., Flores, A., Luna, R. A. & Versalovic, J. Molecular microbiological methods

- 622 in the diagnosis of neonatal sepsis. *Expert Review of Anti-infective Therapy* vol. 8 1037–  
623 1048 Preprint at <https://doi.org/10.1586/eri.10.89> (2010).
- 624 13. Kralik, P. & Ricchi, M. A Basic Guide to Real Time PCR in Microbial Diagnostics:  
625 Definitions, Parameters, and Everything. *Front. Microbiol.* **8**, 108 (2017).
- 626 14. Yang, S. & Rothman, R. E. PCR-based diagnostics for infectious diseases: uses,  
627 limitations, and future applications in acute-care settings. *Lancet Infect. Dis.* **4**, 337–348  
628 (2004).
- 629 15. Øvstebø, R. *et al.* Use of robotized DNA isolation and real-time PCR to quantify and identify  
630 close correlation between levels of *Neisseria meningitidis* DNA and lipopolysaccharides in  
631 plasma and cerebrospinal fluid from patients with systemic meningococcal disease. *J. Clin.*  
632 *Microbiol.* **42**, 2980–2987 (2004).
- 633 16. Hajja, M. *et al.* Limitations of Different PCR Protocols Used in Diagnostic Laboratories: A  
634 Short Review. *Modern Medical Laboratory Journal* vol. 1 1–6 Preprint at  
635 <https://doi.org/10.30699/mmlj17-01-01> (2018).
- 636 17. Taylor, S. C. *et al.* The Ultimate qPCR Experiment: Producing Publication Quality,  
637 Reproducible Data the First Time. *Trends Biotechnol.* **37**, 761–774 (2019).
- 638 18. Klein, D. Quantification using real-time PCR technology: applications and limitations.  
639 *Trends in Molecular Medicine* vol. 8 257–260 Preprint at <https://doi.org/10.1016/s1471->  
640 [4914\(02\)02355-9](https://doi.org/10.1016/s1471-4914(02)02355-9) (2002).
- 641 19. Handschur, M., Karlic, H., Hertel, C., Pfeilstöcker, M. & Haslberger, A. G. Preanalytic  
642 removal of human DNA eliminates false signals in general 16S rDNA PCR monitoring of  
643 bacterial pathogens in blood. *Comp. Immunol. Microbiol. Infect. Dis.* **32**, 207–219 (2009).
- 644 20. Rivas, R., Velázquez, E., Zurdo-Piñeiro, J. L., Mateos, P. F. & Martínez Molina, E.  
645 Identification of microorganisms by PCR amplification and sequencing of a universal  
646 amplified ribosomal region present in both prokaryotes and eukaryotes. *J. Microbiol.*  
647 *Methods* **56**, 413–426 (2004).



- 648 21. Sachse, K. Specificity and Performance of PCR Detection Assays for Microbial Pathogens.  
649 *Molecular Biotechnology* vol. 26 61–80 Preprint at <https://doi.org/10.1385/mb:26:1:61>  
650 (2004).
- 651 22. Hoffmeister, M. & Martin, W. Interspecific evolution: microbial symbiosis, endosymbiosis  
652 and gene transfer. *Environ. Microbiol.* **5**, 641–649 (2003).
- 653 23. O'Brien, T. W. *et al.* Mammalian mitochondrial ribosomal proteins (2). Amino acid  
654 sequencing, characterization, and identification of corresponding gene sequences. *J. Biol.*  
655 *Chem.* **274**, 36043–36051 (1999).
- 656 24. Schwartz, R. M. & Dayhoff, M. O. Origins of Prokaryotes, Eukaryotes, Mitochondria, and  
657 Chloroplasts. *Science* vol. 199 395–403 Preprint at <https://doi.org/10.1126/science.202030>  
658 (1978).
- 659 25. Eperon, I. C., Anderson, S. & Nierlich, D. P. Distinctive sequence of human mitochondrial  
660 ribosomal RNA genes. *Nature* vol. 286 460–467 Preprint at  
661 <https://doi.org/10.1038/286460a0> (1980).
- 662 26. Millar, B. C., Xu, J. & Moore, J. E. Risk assessment models and contamination  
663 management: implications for broad-range ribosomal DNA PCR as a diagnostic tool in  
664 medical bacteriology. *J. Clin. Microbiol.* **40**, 1575–1580 (2002).
- 665 27. Niles, D. T., Wijetunge, D. S. S., Palazzi, D. L., Singh, I. R. & Revell, P. A. Plasma  
666 Metagenomic Next-Generation Sequencing Assay for Identifying Pathogens: a  
667 Retrospective Review of Test Utilization in a Large Children's Hospital. *J. Clin. Microbiol.*  
668 **58**, (2020).
- 669 28. The Next Big Thing? Next-Generation Sequencing of Microbial Cell-Free DNA Using the  
670 Karius Test. *Clin. Microbiol. Newsl.* **43**, 69–79 (2021).
- 671 29. Hu, B. *et al.* A Comparison of Blood Pathogen Detection Among Droplet Digital PCR,  
672 Metagenomic Next-Generation Sequencing, and Blood Culture in Critically Ill Patients With  
673 Suspected Bloodstream Infections. *Front. Microbiol.* **12**, 641202 (2021).

- 674 30. Hogan, C. A. *et al.* Clinical Impact of Metagenomic Next-Generation Sequencing of Plasma  
675 Cell-Free DNA for the Diagnosis of Infectious Diseases: A Multicenter Retrospective Cohort  
676 Study. *Clin. Infect. Dis.* **72**, 239–245 (2021).
- 677 31. Babady, N. E. Clinical Metagenomics for Bloodstream Infections: Is the Juice Worth the  
678 Squeeze? *Clin. Infect. Dis.* **72**, 246–248 (2020).
- 679 32. Niles, D. T., Lee, R. A., Lamb, G. S., Dhaheri, F. A. & Boguniewicz, J. Plasma cell-free  
680 metagenomic next generation sequencing in the clinical setting for the diagnosis of  
681 infectious diseases: a systematic review and meta-analysis. *Diagn. Microbiol. Infect. Dis.*  
682 **105**, 115838 (2023).
- 683 33. Miller, S. & Chiu, C. The Role of Metagenomics and Next-Generation Sequencing in  
684 Infectious Disease Diagnosis. *Clin. Chem.* **68**, 115–124 (2021).
- 685 34. Wang, H. *et al.* Clinical diagnostic application of metagenomic next-generation sequencing  
686 in children with severe nonresponding pneumonia. *PLoS One* **15**, e0232610 (2020).
- 687 35. Benamu, E. *et al.* Plasma Microbial Cell-free DNA Next-generation Sequencing in the  
688 Diagnosis and Management of Febrile Neutropenia. *Clin. Infect. Dis.* **74**, 1659–1668  
689 (2021).
- 690 36. Church, D. L. *et al.* Performance and Application of 16S rRNA Gene Cycle Sequencing for  
691 Routine Identification of Bacteria in the Clinical Microbiology Laboratory. *Clin. Microbiol.*  
692 *Rev.* **33**, (2020).
- 693 37. Dunne, W. M., Westblade, L. F. & Ford, B. Next-generation and whole-genome sequencing  
694 in the diagnostic clinical microbiology laboratory. *Eur. J. Clin. Microbiol. Infect. Dis.* **31**,  
695 1719–1726 (2012).
- 696 38. Deurenberg, R. H. *et al.* Reprint of 'Application of next generation sequencing in clinical  
697 microbiology and infection prevention'. *J. Biotechnol.* **250**, 2–10 (2017).
- 698 39. Bertelli, C. & Greub, G. Rapid bacterial genome sequencing: methods and applications in  
699 clinical microbiology. *Clin. Microbiol. Infect.* **19**, 803–813 (2013).

- 700 40. Boers, S. A., Jansen, R. & Hays, J. P. Understanding and overcoming the pitfalls and  
701 biases of next-generation sequencing (NGS) methods for use in the routine clinical  
702 microbiological diagnostic laboratory. *Eur. J. Clin. Microbiol. Infect. Dis.* **38**, 1059–1070  
703 (2019).
- 704 41. Velez, D. O. *et al.* Massively parallel digital high resolution melt for rapid and absolutely  
705 quantitative sequence profiling. *Sci. Rep.* **7**, 42326 (2017).
- 706 42. Sinha, M., Mack, H., Coleman, T. P. & Fraley, S. I. A High-Resolution Digital DNA Melting  
707 Platform for Robust Sequence Profiling and Enhanced Genotype Discrimination. *SLAS*  
708 *Technol* **23**, 580–591 (2018).
- 709 43. Fraley, S. I. *et al.* Universal digital high-resolution melt: a novel approach to broad-based  
710 profiling of heterogeneous biological samples. *Nucleic Acids Res.* **44**, 508 (2016).
- 711 44. Fraley, S. I. *et al.* Nested Machine Learning Facilitates Increased Sequence Content for  
712 Large-Scale Automated High Resolution Melt Genotyping. *Sci. Rep.* **6**, 19218 (2016).
- 713 45. Langouche, L. *et al.* Data-driven noise modeling of digital DNA melting analysis enables  
714 prediction of sequence discriminating power. *Bioinformatics* **36**, 5337–5343 (2021).
- 715 46. Sinha, M., Mack, H., Coleman, T. P. & Fraley, S. I. A High-Resolution Digital DNA Melting  
716 Platform for Robust Sequence Profiling and Enhanced Genotype Discrimination. *SLAS*  
717 *Technol* **23**, 580–591 (2018).
- 718 47. Aralar, A. *et al.* Improving Quantitative Power in Digital PCR through Digital High-  
719 Resolution Melting. *J. Clin. Microbiol.* **58**, (2020).
- 720 48. Soejima, T., Schlitt-Dittrich, F. & Yoshida, S.-I. Polymerase chain reaction amplification  
721 length-dependent ethidium monoazide suppression power for heat-killed cells of  
722 Enterobacteriaceae. *Anal. Biochem.* **418**, 37–43 (2011).
- 723 49. Fittipaldi, M., Nocker, A. & Codony, F. Progress in understanding preferential detection of  
724 live cells using viability dyes in combination with DNA amplification. *J. Microbiol. Methods*  
725 **91**, 276–289 (2012).


- 726 50. Baymiev, A. K. *et al.* Modern Approaches to Differentiation of Live and Dead Bacteria Using  
727 Selective Amplification of Nucleic Acids. *Microbiology* vol. 89 13–27 Preprint at  
728 <https://doi.org/10.1134/s0026261720010038> (2020).
- 729 51. Chakravorty, S., Helb, D., Burday, M., Connell, N. & Alland, D. A detailed analysis of 16S  
730 ribosomal RNA gene segments for the diagnosis of pathogenic bacteria. *Journal of*  
731 *Microbiological Methods* vol. 69 330–339 Preprint at  
732 <https://doi.org/10.1016/j.mimet.2007.02.005> (2007).
- 733 52. Cruz, A. T. *et al.* Updates on pediatric sepsis. *J Am Coll Emerg Physicians Open* **1**, 981–  
734 993 (2020).
- 735 53. Aralar, A. *et al.* Improving Quantitative Power in Digital PCR through Digital High-  
736 Resolution Melting. *J. Clin. Microbiol.* **58**, (2020).
- 737 54. Hasan, M. R. *et al.* Depletion of Human DNA in Spiked Clinical Specimens for Improvement  
738 of Sensitivity of Pathogen Detection by Next-Generation Sequencing. *J. Clin. Microbiol.* **54**,  
739 919–927 (2016).
- 740 55. Aralar, A. *et al.* Improving Quantitative Power in Digital PCR through Digital High-  
741 Resolution Melting. *J. Clin. Microbiol.* **58**, (2020).
- 742 56. Brunskill, S. *et al.* What is the maximum time that a unit of red blood cells can be safely left  
743 out of controlled temperature storage? *Transfus. Med. Rev.* **26**, 209–223.e3 (2012).
- 744 57. United Kingdom Blood Services. *Handbook of Transfusion Medicine*. (Stationery Office,  
745 2013).
- 746 58. Funes-Huacca, M. E., Opel, K., Thompson, R. & McCord, B. R. A comparison of the effects  
747 of PCR inhibition in quantitative PCR and forensic STR analysis. *Electrophoresis* **32**, 1084–  
748 1089 (2011).
- 749 59. Ayrapetyan, M., Williams, T. & Oliver, J. D. Relationship between the Viable but  
750 Nonculturable State and Antibiotic Persister Cells. *J. Bacteriol.* **200**, (2018).
- 751 60. Marchant, E. A., Boyce, G. K., Sadarangani, M. & Lavoie, P. M. Neonatal sepsis due to

- 752 coagulase-negative staphylococci. *Clin. Dev. Immunol.* **2013**, 586076 (2013).
- 753 61. Wain, J. *et al.* Quantitation of bacteria in bone marrow from patients with typhoid fever:  
754 relationship between counts and clinical features. *J. Clin. Microbiol.* **39**, 1571–1576 (2001).
- 755 62. Mogasale, V., Ramani, E., Mogasale, V. V. & Park, J. What proportion of Salmonella Typhi  
756 cases are detected by blood culture? A systematic literature review. *Ann. Clin. Microbiol.*  
757 *Antimicrob.* **15**, 32 (2016).
- 758 63. Massi, M. N. *et al.* Quantitative detection of Salmonella enterica serovar Typhi from blood  
759 of suspected typhoid fever patients by real-time PCR. *Int. J. Med. Microbiol.* **295**, 117–120  
760 (2005).
- 761 64. Brooke, J. S. New strategies against *Stenotrophomonas maltophilia*: a serious worldwide  
762 intrinsically drug-resistant opportunistic pathogen. *Expert Rev. Anti. Infect. Ther.* **12**, 1–4  
763 (2014).
- 764 65. Brooke, J. S. *Stenotrophomonas maltophilia*: an emerging global opportunistic pathogen.  
765 *Clin. Microbiol. Rev.* **25**, 2–41 (2012).
- 766 66. Said, M. S., Tirthani, E. & Lesho, E. *Stenotrophomonas Maltophilia*. in *StatPearls*  
767 (StatPearls Publishing, 2022).

768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783


784  
785  
786  
787  
788  
789  
790

**FIGURES**




791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804

**Figure 1. Digital melt curve database creation and algorithm training.** Eleven organisms were individually spiked into whole blood, processed with Molysis, and analyzed by U-dHRM with V1F/V9R primers and IAC. A) Plot of representative digital melt curve signature for each organism with the IAC curve region cropped out for visualization purposes. Raw organism curves are shown in Supplementary Fig. 7. B) Confusion matrix showing digital melt curve classification results for the machine learning algorithm.



805  
806  
807  
808  
809  
810  
811  
812  
813

**Figure 2. Analytical validation of U-dHRM on spiked whole blood samples.** A) Schematic showing the procedure for analytical validation studies comparing U-dHRM to quantitative blood culture. B) Plot comparing quantification of bacteria by U-dHRM versus culture. A 6-fold dilution series of *E. coli* was prepared in PBS and spiked into whole blood. Controls included blank PBS spiked into blood and an extraction blank (EB, Molzyme SU buffer alone as input for Molysis processing). It is assumed that one 16S copy/melt curve will be detected per CFU.



814  
 815 **Figure 3. Pilot clinical testing on whole blood samples.** A-I) Representative organism curves  
 816 (red) that were matched with high confidence to database curves (black) by the machine  
 817 learning algorithm in each CBC sample. No curves were detected in CBC negatives. The  
 818 number of melt curves detected for each organism (cluster) is noted in the legends. J) Load of  
 819 individual clinically relevant organisms identified and quantified by U-dHRM in CBC samples.  
 820  
 821



822 **TABLES**


823

824 **Table 1. Comparison of clinical diagnostics and U-dHRM results.**

No.	Clinical TTR	Cultured Organism	ePlex BCID Result	Preliminary Diagnosis	Final Diagnosis	Clinician Adjudication	U-dHRM ID	U-dHRM Confidence Level
1	0d, 22hr, 44min	<i>S. epidermidis</i> (CoNS)	<i>S. epidermidis</i> (CoNS)	Acute UTI + Fever	<i>E. coli</i> UTI	Negative	CoNS	High
2	2d, 12hr, 54min	<i>S. enterica</i> Typhi	<i>S. enterica</i> Typhi	Acute febrile illness in child	<i>S. enterica</i> Typhi BSI	Positive <i>S. enterica</i>	<i>S. enterica</i>	High
3	3d, 0hrs, 45min	<i>S. enterica</i> Typhi	<i>S. enterica</i> Typhi	<i>Salmonella</i> BSI	<i>S. enterica</i> Typhi BSI	Positive <i>S. enterica</i>	<i>S. enterica</i> , <i>S. maltophilia</i>	High
4	0d, 13hr, 24min	<i>S. maltophilia</i>	<i>S. maltophilia</i>	BSI	<i>S. maltophilia</i> CLABSI	Positive <i>S. maltophilia</i>	<i>S. maltophilia</i>	High
5	1d, 12hr, 20min	<i>Salmonella</i> spp.	Negative	<i>Salmonella</i> BSI	<i>S. enterica</i> BSI	Positive <i>S. enterica</i>	<i>S. enterica</i> , <i>S. aureus</i>	High
6	0d, 16hr, 59min	GPR	Bacteroides	Cellulitis	Poly-microbial SSTI	Negative	CoNS	High
7	0d, 16hr, 36min	GNR	<i>Enterobacter non cloacae</i>	BSI	<i>Klebsiella</i> CLABSI	Positive <i>Klebsiella</i>	<i>K. pneumoniae</i>	Low

825 \*CoNS = Coagulase Negative *Staphylococci*; BSI = Bloodstream Infection; UTI = Urinary Tract Infection; CLABSI =  
 826 Central Line Associated BSI; SSTI = Skin and Soft Tissue Infection.

827



**b**

True Class \ Predicted Class	CoNS	EC	EF	GBS	KP	PA	SA	SE	SM	SP
CoNS	91.0%	0.0%	0.0%	0.7%	0.0%	0.0%	8.1%	0.0%	0.0%	0.0%
EC	0.0%	96.0%	3.2%	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%	0.7%
EF	0.0%	4.2%	95.0%	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%	0.5%
GBS	0.4%	0.0%	0.2%	98.2%	0.8%	0.0%	0.0%	0.0%	0.0%	0.4%
KP	0.1%	0.2%	0.0%	0.4%	96.9%	0.1%	0.0%	1.6%	0.0%	0.7%
PA	0.2%	0.0%	0.0%	0.4%	0.0%	99.2%	0.0%	0.1%	0.0%	0.0%
SA	7.2%	0.0%	0.0%	0.0%	0.0%	0.0%	92.8%	0.0%	0.0%	0.0%
SE	0.0%	0.0%	0.0%	0.1%	0.5%	0.3%	0.0%	98.7%	0.3%	0.0%
SM	0.1%	0.0%	0.1%	0.1%	0.0%	0.0%	0.0%	2.2%	97.5%	0.0%
SP	0.3%	0.1%	0.0%	0.0%	0.1%	0.0%	0.2%	0.0%	0.0%	99.2%

### U-dHRM Quantification

